KAIST reverses colon cancer cells

KAIST researchers reported in a paper posted by *Advanced Science* on May 13 that they pushed colorectal cancer cells toward a normal-like state by suppressing three regulators — MYB, HDAC2 and FOXA2. The study, led by Kwang-Hyun Cho and first-authored by Jeong-Ryeol Gong, described results in cultured colorectal cancer cells and in mouse experiments. (pmc.ncbi.nlm.nih.gov) The paper said the triple intervention induced enterocyte differentiation and reduced malignant features, rather than aiming to kill the cells outright. ### What exactly did the KAIST team say it changed? The May 13 paper said the group used a computational framework called single-cell Boolean network inference and control, or BENEIN, to model how normal large-intestinal cells differentiate. (pmc.ncbi.nlm.nih.gov) From that model, the researchers identified MYB, HDAC2 and FOXA2 as “master regulators” whose inhibition could drive cells toward an enterocyte state. The authors wrote that simultaneous knockdown of those three regulators reverted colorectal cancer cells into “normal-like enterocytes” by inducing differentiation and suppressing malignancy. KAIST said in a December 2024 research summary that the finding was confirmed through molecular, cellular and animal studies. (pmc.ncbi.nlm.nih.gov) ### Why are MYB, HDAC2 and FOXA2 the center of the story? MYB, HDAC2 and FOXA2 were the three genes the model singled out as top control factors in the colon-cell differentiation program, according to the paper and KAIST’s research summary. The study’s premise was that cancer development can involve cells moving backward along a differentiation path, and that steering them forward again could restore normal-like behavior. (pmc.ncbi.nlm.nih.gov) Kwang-Hyun Cho’s team said in the paper that the effect depended on simultaneous perturbation, not just one regulator at a time. The article abstract described the result as a synergistic effect, with the three-gene suppression working together to produce the reversion phenotype. (pmc.ncbi.nlm.nih.gov) ### Did this happen in patients? The paper described laboratory and mouse-model results, not a human trial. KAIST’s December 2024 summary said the work was validated in vitro and in vivo, and the published article identified the outcome as reversion of colorectal cancer cells into a normal-like state in experimental systems. (pmc.ncbi.nlm.nih.gov) The February 2025 KAIST research update described related work from Cho’s group on identifying a “molecular switch” around the transition from normal to cancer cells in colon cancer. That update said the team had confirmed recovery of normal-cell characteristics in molecular cell experiments, again pointing to a preclinical stage rather than clinical use. (pmc.ncbi.nlm.nih.gov) ### What is the practical claim here — treatment or proof of concept? The *Advanced Science* article presented the work as a framework for “cancer reversion,” using network analysis to identify control points in cell fate. KAIST said the approach was designed to convert cancer cells into a state resembling normal colon cells without killing them. (pmc.ncbi.nlm.nih.gov) KAIST’s February 2025 statement said the broader aim was to build reversion therapies for other cancers as well. That remains a future step: the material available now is an open-access research paper and institutional summaries describing preclinical findings and the computational method behind them. (news.kaist.ac.kr) ### Where can readers check the study themselves? The paper is listed in *Advanced Science* as article number 2402132 with DOI 10.1002/advs.202570019, and PubMed Central hosts the open-access version. The author list shown there includes Jeong-Ryeol Gong, Chun-Kyung Lee, Hoon-Min Kim, Juhee Kim, Jaeog Jeon, Sunmin Park and Kwang-Hyun Cho. (pmc.ncbi.nlm.nih.gov) KAIST’s next public step, based on its February 2025 statement, is to extend the reversion-switch approach to other cancers. For now, the named participants attached to this line of work remain Cho’s laboratory at KAIST and the co-authors on the *Advanced Science* paper. (pmc.ncbi.nlm.nih.gov) (news.kaist.ac.kr)